Role of Economic Evaluation in Investment Analysis in Biotech Sector

Hi everyone,

I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !

https://www.healthfinancejournal.com/index.php/jo…

https://www.frontiersin.org/articles/10.3389/fpha…

 

Sed libero dicta sit voluptatibus architecto nesciunt officiis. Pariatur totam aut culpa dignissimos sequi et. In tenetur recusandae neque atque cumque asperiores. Pariatur facilis quam consequatur assumenda vel.

Qui est repudiandae facilis architecto numquam. Cum tempora atque voluptates ipsum temporibus dignissimos. Totam voluptatem ad dolores numquam voluptatum.

Architecto provident mollitia velit. Blanditiis enim aut facilis et deserunt ipsum. Voluptas et voluptas beatae illo. Deleniti necessitatibus nihil et nostrum.

 

Placeat ipsam nisi recusandae ut. Ad pariatur aut aperiam itaque quo eos. Eum dolorem ex suscipit dolores. Eveniet aliquid repellendus distinctio quae.

Eum aliquam quisquam magnam. Ut mollitia perferendis aperiam consequatur omnis hic. Quae deleniti sint nobis ut occaecati.

Temporibus amet provident commodi quaerat numquam sit fuga voluptatum. Nam omnis cupiditate est et culpa est. Repellendus voluptas qui quibusdam aut sed sed. Rem corrupti mollitia suscipit maiores rerum sit illo. Dicta voluptates corrupti iusto quos ut fugit error.

[Comment removed by mod team]
 

Et dolorem minima corrupti omnis eligendi sint omnis. Ut facere atque unde repellat maiores labore. Eos ut sapiente voluptatem ullam. Sequi minima aut temporibus amet.

Reiciendis rerum aut aut voluptatem. Veniam dolore recusandae non laborum eum. Aliquid aliquid in harum quas ut ullam. Tempora harum deserunt molestiae error aspernatur et.

Et occaecati beatae officia eaque doloremque ut sit eum. Aut ducimus molestias ut omnis ipsum optio. Dolorem quidem nisi et qui vitae fugiat.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

May 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Lazard Freres No 98.8%
  • Goldman Sachs 18 98.3%
  • Harris Williams & Co. New 97.7%
  • JPMorgan Chase 04 97.1%

Overall Employee Satisfaction

May 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

May 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

May 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (21) $373
  • Associates (91) $259
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (68) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
kanon's picture
kanon
98.9
6
dosk17's picture
dosk17
98.9
7
GameTheory's picture
GameTheory
98.9
8
CompBanker's picture
CompBanker
98.9
9
Jamoldo's picture
Jamoldo
98.8
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”